The Safeway Foundation provided the National Foundation for Cancer Research (NFCR) a $50,000 grant to support innovative oncology research. The donation has been designated to NFCR Fellow Paul B. Fisher, M.Ph., Ph.D., at the Virginia Commonwealth University School of Medicine. The funds from The Safeway Foundation are being used to help sustain Dr. Fisher’s research on enhancing his promising immunotherapy for metastatic prostate and other cancers: the aptly named Cancer Terminator Virus.
Dr. Fisher’s cutting edge technology has been shown to produce profound anti-cancer activity in slowing or halting metastatic—spreading—cancer, which is responsible for 90% of the lives lost to the disease.
Last year, Albertsons Companies Foundation and its 12 subsidiaries, including the Safeway Foundation, donated more than $18 million to improve the quality of life of their customers and the communities they serve.
“We are grateful to the Safeway Foundation for their generous support to help us fund the research for treatments against one of the deadliest elements of cancer,” said NFCR CEO Franklin C. Salisbury, Jr. “Thank you, Safeway, for joining Research for a Cure!”